Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials
Renier Brentjens, MD, PhD, has spent most of his career pioneering research into the development and use of CAR T-cell therapies in the hopes of finding innovative and effective treatments for cancer.
Clinical Scorecard: Roswell Park Accelerates CAR T-Cell Innovation with Upcoming Trials
At a Glance
Category Detail
Condition Cancer Key Mechanisms CAR T-cell therapy reeducates the immune system to recognize and attack cancer cells. Target Population Patients with blood cancers and solid tumors, including osteosarcoma, small-cell lung cancer, and ovarian cancer. Care Setting Roswell Park Comprehensive Cancer Center
Key Highlights
Roswell Park is expanding CAR T-cell therapy trials for solid tumors. Upcoming trials will target osteosarcoma, small-cell lung cancer, and ovarian cancer. CAR T-cell therapy has shown success in blood cancers but requires further development for solid tumors. The center collaborates with other institutions and biotech companies for innovative trials. Next-generation trials are available for patients who have relapsed after previous therapies. Guideline-Based Recommendations
Diagnosis
Identify eligible patients with blood cancers and solid tumors for CAR T-cell therapy. Management
Utilize CAR T-cell therapy for patients with acute myelogenous leukemia and other blood cancers. Monitoring & Follow-up
Monitor patients for toxicities associated with CAR T-cell therapy and bone marrow transplants. Risks
Potential complications from CAR T-cell therapy include cytokine release syndrome and neurotoxicity. Patient & Prescribing Data
Patients with relapsed or refractory blood cancers and solid tumors.
CAR T-cell therapy is FDA approved for certain blood cancers; ongoing trials aim to expand its application.
Clinical Best Practices
Ensure specialized care for patients receiving CAR T-cell therapy. Stay updated on emerging clinical trials and novel targets for CAR T-cell therapy. References
